Inflammatory cells in ischemic acute renal failure  by Friedewald, John J. & Rabb, Hamid
486 Forefronts in Nephrology
Inflammatory cells in ischemic acute renal failure
JOHN J. FRIEDEWALD and HAMID RABB
Renal Divisions, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania; and Johns Hopkins Hospital, Baltimore,
Maryland
Inflammatory cells in ischemic acute renal failure. Ischemic
acute renal failure (ARF) is increasingly recognized as involving
a complex cascade of mechanisms with both acute and chronic
consequences. Attention to nontraditional mediators of ARF
such as inflammatory pathways and microvascular events has
yielded new paradigms and avenues of research.
The initiation phase of renal ischemia/reperfusion (I/R) in-
jury damage involves microvascular hemodynamic changes
characterized by red blood cell sludging with platelets and
leukocytes. Blocking leukocyte-endothelial interactions has
yielded significant protection from renal I/R injury in experi-
mental models. However, experiments focusing on the role of
the neutrophil have led to a modest expectation of its role in
ARF. Recent studies have found that T cells directly mediate
renal injury in experimental I/R injury. The CD4+ T cell, work-
ing both via interferon-c (IFN-c) and costimulatory molecules
appears to be an important modulator of ARF. The B cell has re-
cently been implicated in ARF. Little is known about the role for
the macrophage. Finally, resident kidney cells likely contribute
to the inflammatory pathogenesis of I/R damage and protec-
tion/repair, but how, and to what extent they are involved is not
known.
New tools to modulate inflammatory cells, particularly
mononuclear leukocytes, hold promise for clinical trials in ARF.
Ischemic acute renal failure (ARF) is increasingly rec-
ognized as involving a complex cascade of mechanisms
with both acute and chronic consequences. Renal is-
chemia/reperfusion (I/R) injury is the major cause of
ARF in both native and transplanted organs. There is
no specific therapy for ARF except for supportive care.
Attention to nontraditional mediators of ARF such as
inflammatory pathways and microvascular events has
yielded new paradigms and avenues of research. We pro-
pose an integrated microvascular inflammation model as
an important pathophysiologic mechanism during the ini-
tiation and extension phase of ischemic ARF. Targeting
pathways within this area will hopefully lead to new ther-
apies for ARF in I/R injury.
Initiation of ARF: Microvascular events
The effects of I/R injury initially begin in the regions of
the kidney most vulnerable to hypoxia, which then trigger
downstream events. Although the kidney receives 25%
of cardiac output, the majority of that flow is directed
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to the renal cortex [1], with only a small fraction reach-
ing the vasa recta of the renal medulla. This area of low
blood flow drives the concentration of urine but ironically
places the medulla at risk of further ischemic damage. Un-
like the renal cortex with a partial pressure of oxygen of
about 50 mm Hg, the outer medulla has a partial pressure
of oxygen in the 10 to 20 mm Hg range [2]. Slight pertur-
bations in blood flow and oxygen delivery to the medulla
can therefore lead to anoxic injury. Ischemic injury leads
to tubular dysfunction and salt wasting [3–5] with a result-
ing increase in sodium delivery, which promotes glomeru-
lar vasoconstriction and decreased glomerular filtration
through tubuloglomerular feedback [2].
Local medullary anoxia leads to depletion of cellular
energy stores and disruption of the actin cytoskeleton in
endothelial cells and vascular smooth muscle cells [6, 7].
The resulting cellular deformities and surrounding tissue
hypoxia, as well as endothelial-erythrocyte inteactions,
promote erythrocyte sludging in the ascending vasa recta
analogous to a vaso-occlusive sickle cell crisis (Fig. 1).
Neutrophils
Neutrophils have been the most widely studied inflam-
matory cells in I/R injury. Their migration into brain and
cardiac tissue following I/R injury is well established [8,
9]. Although neutrophils are identifiable in renal tissue
following ischemic injury in animals [10–14], few infil-
trating neutrophils are found in human ARF biopsies.
In experimental renal I/R injuries, some studies have
demonstrated that decreased renal injury occurs when
neutrophil migration and activity are blocked while most
others have not found a protective effect of neutrophil
blockade or depletion on the course of ARF [15, 16]. The
neutrophil may contribute to plugging in the microvas-
culature and subsequently release oxygen free radicals
and proteases, and is less likely to directly affect tubular
function (Table 1).
Though studies targeting neutrophils directly have not
led to new therapies, major and consistent protection dur-
ing experimental renal I/R injury has been afforded by
targeting adhesion molecules originally thought to only
mediate neutrophil function. Early inflammation is clas-
sically characterized by margination of neutrophils to
vascular endothelium. Tethering interactions between
selectins and their ligands initially slows neutrophils,
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Fig. 1. Stains of human cadaveric kidney with ischemic acute tubular
necrosis (ATN) 1 week post-transplant. (A) Hematoxylin and eosin
stain. The patient exhibited delayed graft function in the absence of
rejection and calcineurin-inhibitor toxicity. Shown are dilated and con-
gested capillaries with numerous inflammatory cells [mostly mononu-
clear (large arrow)] and red blood cells (small arrow) in the vasa recta
in outer medulla. (B) Immunoperoxidase stain for T cells (CD3) in the
same case. Note that many but not all of the cells in the capillaries are
positive (arrows).
allowing firmer adhesion and transmigration by integrins
and their ligands. It was initially found that blockade of
P-selectin protected from ischemic ARF in the rat [ab-
stract; Rabb H, ASN, 1994], and later Singbartl, Forlow,
and Ley [17] found that it was platelet P-selectin and not
endothelial P-selectin which was the main determinant
of the P-selectin–mediated renal injury. Blockade of the
shared ligand to all three selectins (E-, P-, and L-selectin)
significantly protected rats from both renal I/R injury and
associated mortality [12]. A key fucosyl sugar on the se-
lectin ligands appears to be the critical determinant of the
renal injury after ischemia [18]. Both in rats and mice,
selectin ligand blockade, initially targeted to abrogate
neutrophil infiltration, resulted in renal protection while
neutrophils continued to infiltrate the postischemic kid-
ney. Interestingly, neutrophil depletion in the rat model
did not lead to protection [19], while it was protective
Table 1. Infiltration of inflammatory cells into the kidney and
mediation of injury following ischemia/reperfusion injury
Phase of infiltration
into kidney
Direct role in
Cell type Initiation Extension Repair pathogenesis
Neutrophils ++ + − Likely a modest role as
an effector cell
Macrophages + ++ +/− No evidence yet, likely
involved in repair
T cells ? + ++ Early modulatory role
B cells ? + ? Probable modulatory
role
Platelets ++ + ? Suggestive data, likely
early mediator
in the mouse [20]. The varying degrees of neutropenia
attained by the interventions may have influenced the
different outcomes.
After the initial slowing of leukocytes by selectins,
firm adhesion is imparted by integrins with intercel-
lular adhesion molecule-1 (ICAM-1). Blockade of the
integrin CD11/CD18 led to significant protection from
experimental I/R injury–induced ARF in rats [19]; mice
deficient in ICAM-1 were also found to have relative pro-
tection from renal ischemic injury [20]. The importance of
ICAM-1 interactions has also been studied in human re-
nal transplant models. An initial study showed treatment
with anti-ICAM-1 (or CD54) monoclonal antibodies pro-
tected human patients receiving a “high-risk” cadaveric
renal allograft. Their rates of delayed graft function were
lower than patients not treated with the antibody that
received the sister organ [21]. More recently, a random-
ized, controlled trial of anti-ICAM-1 monoclonal anti-
body in recipients of cadaveric renal transplants showed
that short-term induction with anti-ICAM-1 did not re-
duce the rate of delayed graft function or acute rejec-
tion [22]. A major problem is that experimental studies
demonstrate a dramatic protection by adhesion molecule
blockade when given preischemia, while human studies
have administered adhesion blockade after ischemia.
Chiao et al [13] treated mice and rats with a-
melanocyte-stimulating hormone (a-MSH), a known
inhibitor of interleukin (IL)-8 (a murine neutrophil
chemokine) and ICAM-1 induction. They found signif-
icantly less renal damage following I/R injury, both by
measurements of serum creatinine and by renal histology.
In a follow-up study [23] it was demonstrated that a-MSH
inhibited renal injury in a neutrophil-depleted model,
suggesting a more complex role for a-MSH possibly by
acting directly on renal tubular cells. Still other studies
demonstrating a protection by an anti-inflammatory in-
tervention had attributed the mechanism of protection to
neutrophil blockade. A2A adenosine receptor blockade
[24] leads to renoprotective effects in I/R injury models.
Initially thought to mediate injury through neutrophils,
recent elegant work confirms a key leukocyte media-
tion, but through mononuclear cells [25, 26]. Blockage
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Fig. 2. Electron micrograph of human kidney with acute tubular necro-
sis (ATN), showing granulocytes (large arrow) and mononuclear cells
(small arrow) aggregating in a peritubular capillary (star denotes an
endothelial cell).
of platelet-activating factor (PAF), thought to play a me-
diating role in neutrophil adherence to endothelium, was
protective in a rat cold I/R model [27]. With the large body
of evidence now implicating the role of the neutrophil in
renal I/R injury damage, the cumulative results suggest
a real but modest role for the neutrophil in I/R injury.
Studies showing protection from I/R injury despite neu-
trophil migration into the kidney suggest that migration
into the organ is not the key mechanisms, similar to what
is now know in asthma [28].
T cells
Based on classic models of tissue injury, the T cell was
not suspected to play a role in ischemic ARF. However,
classic studies on human ARF had identified predomi-
nately mononuclear leukocytes, not neutrophils, in the
vasa recta [29]. T cells and neutrophils can be visualized
in human kidney ischemic ARF using immunostaining
and electron microscopy (Figs. 1 and 2). The produc-
tion of T-cell–associated cytokines occurs in experimental
I/R injury [30]. In addition, the same leukocyte adhesion
molecules targeted for neutrophil blockade in renal I/R
injury, selectins, CD11/CD18 and ICAM-1, also mediate
T-cell adhesion. There are also many experimental stud-
ies in organs other than the kidney (liver, intestine, heart,
and lung) identifying T cells after I/R injury [31]. Using
special stains, T cells have been identified in the kidneys
of rats [32] and mice [33] following I/R injury. This led to
studies that have now identified a modulatory role for T
cells in experimental ARF. Double CD4/CD8 knockout
mice had renal protection from I/R injury [33]. This study
also demonstrated that in vitro hypoxia-reoxygenation of
renal epithelial cells in culture increased T-cell adhesion
within hours in the absence of alloantigen. In a follow-up
study, T-cell–deficient (nu/nu) knockout mice were sub-
jected to renal I/R injury. They also had less depression
of kidney function following I/R injury when compared
to wild-type mice. Adoptive transfer of T cells from wild-
type animals into the (nu/nu) mice restored ischemic in-
jury, reinforcing the role of the T cell in ischemic injury
[34]. To further define the roles of CD4+ and CD8+ cells,
mice lacking only CD4+ T cells, but not CD8+ T cells
were subjected to I/R injury. These mice were also pro-
tected from ischemic renal injury. The CD4+ T cell ef-
fect was found to require interferon-c (IFN-c) and the
B7-CD28 pathway. Experiments in mutant mice, though
mechanistically revealing, may be complicated by re-
sponses other than those originally targeted. In wild type
mice depleted of T cells to very low levels, particularly of
CD4+ cells, significant protection from renal I/R injury
was seen [35]. Alternative approaches using CTLA4Ig to
block the B7-CD28 interaction significantly attenuated
renal dysfunction in a rat renal I/R injury model [36].
De Greef et al [37] found that the B7-1 and not the B7-
2 pathway was the important T-cell costimulatory path-
way. They also localized B7-1 in the endothelial cells in
the ascending vasa recta and postulated that early T-cell
involvement with the microvasculature was contributory.
T cells are more prominent late after ARF and early in-
flux into the kidney has not been studied well. An early,
transient increase in T cells, a “hit-and-run” hypothesis,
might explain how T cells could still have a role without
clear histologic evidence of their presence in tissue in the
first 12 hours postischemia. The data demonstrating an
important role for T cells in renal I/R injury are consis-
tent with emerging data from other organs of the role for
T cells in ischemic injury [31, 38].
Based on more recent data, the role of the T cell in re-
nal I/R injury is more complex than initially expected.
Recent evidence suggests that the Th1 phenotype of
T cells is deleterious, and the Th2 phenotype is protective.
These data, elicited with STAT6- and STAT4-deficient
mice that have impaired Th2 and Th1 responses, respec-
tively, is opposite to the asthma model of T-cell engage-
ment [39]. In addition, mice deficient in both T and B cells
are not protected from renal I/R injury [40]. This may be
in part due to enhanced innate immunity in these mice,
from up-regulation of natural killer (NK) cells. Identifi-
cation of the role of the T cell in renal I/R injury opens
up the opportunity to evaluate well-characterized T-cell
reagents to prevent and treat ARF. In addition, this line
of research extends conventional immunologic dogma on
the T-cell response.
Forefronts in Nephrology 489
B cells
Recognition of the role of the B cell in renal I/R injury
is evolving. There is now evidence that B cells play a role
in I/R injury. B-cell–deficient mice subjected to renal I/R
injury had significant protection from renal damage when
compared to wild-type mice [41]. Transfer of serum from
wild-type to B-cell–deficient mice restored injury, impli-
cating a role for a soluble product such as antibody. Inter-
estingly, patients with myeloma have increased suscepti-
bility to ARF due to high levels of antibody, consistent
with this experimental observation.
Monocytes/macrophages
Macrophages migrate into the outer medulla of rat kid-
ney following I/R injury [14, 42]. Macrophage chemoat-
tractants [e.g., monocyte chemoattractant protein-1
(MCP-1)] are up-regulated during experimental I/R in-
jury [33, 34, 43]. There is as yet little evidence that the
macrophage plays a role in renal injury following I/R
injury, though may be involved in repair. This is sup-
ported by data from osteopontin knockout mice that had
decreased macrophage infiltration into the postischemic
kidney [44]. Although the course of acute renal dysfunc-
tion was similar between osteopontin knockout and wild-
type mice, the mice with fewer infiltrating macrophages
had significantly less fibrosis. Modulation of macrophages
could be useful to improve repair mechanisms.
Red blood cells
As mentioned above, red blood cell sludging has
been identified in the renal medulla following I/R in-
jury [45]. Recent, elegant studies using videomicroscopy
have shown sluggish red blood cell flow through corti-
cal peritubular vessels [46]. The patency of peritubular
capillaries during early reperfusion was partially com-
promised but recovered. This was in contrast to glomeru-
lar vessels, which maintained their patency throughout
reperfusion. Also, peritubular capillaries took more time
to recover normal flow than did glomerular capillaries.
These findings point to a vascular endothelial dysregula-
tion, but whether red blood cells are directly involved,
either through cell adhesion molecules or some other
mechanism, is not known. Interestingly, lowering the
hematocrit ameliorated renal insufficiency in a rat I/R
injury model, but blocking clot aggregation with acetyl
salicylic acid or heparin had no effect [47].
Resident kidney cells
At least two types of resident kidney cells actively
participate in the renal inflammatory response during
ischemic ARF. Tubular epithelial cells show the most
striking morphologic changes following I/R injury [i.e.,
acute tubular necrosis (ATN)]. However, tubular epithe-
lial cells may not be passive victims of renal I/R injury,
but may actively participate in the process, positively or
negatively. These cells have been shown to up regulate
intercellular adhesion molecules, namely ICAM-1 in re-
sponse to I/R injury [48]. Other experiments have shown
an up-regulation of complement factor C5a on tubular
epithelial cells [49]. Blocking C5a decreased renal I/R in-
jury damage, despite infiltration of neutrophils into the
area affected.
Like the T cell, the tubular epithelium could also
play a complex, even protective role in I/R injury. Infu-
sions of bone morphogenic protein-7 (BMP-7) reduced
the severity of injury after I/R injury in the rat kidney
[50, 51]. BMP-7 is expressed in renal tubular epithelial
cells and down regulates chemokines, cytokines, and va-
soregulatory signals [51, 52]. Interestingly, BMP-7 is not
expressed in tubular epithelial cells at highest risk of is-
chemic damage (proximal tubule, thin descending limb,
loop of Henle, or in the peritubular vasculature).
Dendritic cells may also participate in renal I/R injury.
In the absence of acute rejection in a rat transplant I/R
injury model [53], a population of recipient major his-
tocompatibility complex (MHC) class II–positive leuko-
cytes stained in the renal medulla and cortex. Through
immunohistochemical staining, some of these cells were
shown to be dendritic cells. Their role in renal I/R in-
jury damage is yet to be defined, but their appearance
around the time of injury supports further research into
their function.
CONCLUSION
Recognition of the inflammatory cell component of
ARF after I/R injury is now an established area of re-
search. With an understanding of which cell types are
involved in I/R injury and a better understanding of their
complex interactions, effective therapies may well be
forthcoming. Clinical trials are already in final planning
and execution targeting cellular inflammation in ARF.
Drawing from the experience with modifications of the
immune system following human transplantation, some
of the tools needed to improve the morbidity and mor-
tality from this common condition may already exist.
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T cells as mediators in renal ischemia/reperfusion injury
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T cells as mediators in renal ischemia/reperfusion injury. Inflam-
mation has been established to contribute substantially to the
pathogenesis of ischemia/reperfusion (I/R) with a central role
for particular cells, adhesion molecules, and cytokines. Until
recently, most of the research trying to unravel the pathogen-
esis of I/R injury has been focused on the role of neutrophils.
However, recent studies have brought evidence that T cells and
macrophages are also important leukocyte mediators of renal
and extrarenal (liver) I/R injury. In vivo depletion of CD4+ cells
but not CD8+ cells in wild-type mice was protective in I/R of
the kidney. A marked preservation of liver function was also
found after I/R in T-cell deficient athymic mice. Blocking the
B7/CD28 costimulatory pathway by CTLA-4 Ig (recombinant
fusion protein) ameliorated renal dysfunction and decreased
mononuclear cell infiltration in I/R of the kidney. B7-1 expres-
sion was found limited to the membrane of the endothelial
cells of the ascending vasa recta, resulting in trapping of CD28-
expressing CD4 T cells. This trapping of leukocytes results in
the upstream congestion in the ascending arterial vasa recta,
generating the since more than 150 years described medullary
vascular congestion of the kidney soon after ischemic injury.
It seems worthwhile to study a combination therapy using anti-
inflammatory/anti-adhesion molecules in the early phase of I/R.
Acute renal failure (ARF) is a common renal disease
affecting about 5% of all hospitalized patients. ARF still
carries a very high mortality of more than 50% and there
has been almost no significant change in mortality over
the last four decades [1, 2]. The kidney is highly vul-
nerable to the deleterious effects of renal hypoperfusion
(ischemia) and to many toxic substances, or a combina-
tion of both. Renal ischemia/reperfusion (I/R) injury is
the major cause of ARF in the native [3] as well as in the
transplanted kidney [4]. Although the renal functional
decline may be very pronounced, it is remarkable that the
acutely injured kidney has a striking regeneration capac-
ity. As opposed to chronic renal failure, in the majority
of cases of ARF the kidney will regain complete func-
tionality in the absence of interstitial inflammation and
fibrosis.
Key words: T cells, ascending vasa recta, medullary congestion, inflam-
mation.
There is no specific treatment for this devastating clin-
ical syndrome, reflecting, in part, the relatively poor un-
derstanding of the pathophysiology of this disease [5].
The pathogenesis of I/R injury is complex, but inflam-
mation is an established feature. Indeed, a manifest and
intriguing effect during acute tubular necrosis (ATN) and
repair is the prompt appearance, immediately following
injury, and disappearance of inflammatory cells when the
regeneration is complete. Both detrimental and regen-
erative potentials have been ascribed to these cells [6].
Although the literature on the possible role of these in-
terstitial leukocytes is abundant, their exact initiating and
resolving mechanisms and their effect on early and final
outcome of ARF are still unclear. Until recently, most of
the research unraveling the pathogenesis of I/R injury has
been focused on the role of the neutrophil [5]. However,
recent studies have brought evidence that T cells could
be also important leukocyte mediators of renal and ex-
trarenal (liver) I/R injury [7–10].
LEUKOCYTE ADHESION/INFILTRATION
AFTER I/R INJURY
Despite much attention to the role attributed to leuko-
cytes in I/R injury of different organs, the composition
and the kinetics of this infiltrate in relation to the evolu-
tion of the pathology is still not clearly defined. In the kid-
ney, polymorphonuclear cells (PMNs) recruited during
reperfusion have been considered as critical mediators
of the early parenchymal injury in ischemic ARF. How-
ever, clear evidence demonstrating that the number of
PMNs has a critical role on outcome of ARF is still
lacking [11]. On the other hand, the presence of mono-
cytes/macrophages and T cells in experimental models of
I/R injury seems to be consistent. Depending on the renal
insult, the kinetics of this mononuclear infiltrate (mono-
cytes/macrophages and T cells) may vary as well as the
participation of other leukocytes (B cells, PMNs, etc.). It
is remarkable that macrophages and T lymphocytes re-
main localized predominantly in the zone of most severe
injury, which is the outer stripe of the outer medulla [12].
